GW Pharmaceuticals PLC- (GWPH) Stock Rating Lowered by Zacks Investment Research

GW Pharmaceuticals PLC- (NASDAQ:GWPH) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report released on Monday.

According to Zacks, “GW Pharmaceuticals plc is a biopharmaceutical company focused on discovering, developing and commercializing therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. The Company’s lead product, Sativex is used for the treatment of MS symptoms, cancer pain, and neuropathic pain. It operates primarily in the United Kingdom, Europe, the United States, Canada, and Asia. GW Pharmaceuticals plc is based in Salisbury, the United Kingdom. “

GWPH has been the topic of a number of other reports. Leerink Swann boosted their price objective on shares of GW Pharmaceuticals PLC- from $153.00 to $157.00 and gave the company an “outperform” rating in a report on Tuesday, February 6th. Bank of America dropped their price objective on shares of GW Pharmaceuticals PLC- from $154.00 to $149.00 and set a “buy” rating on the stock in a report on Tuesday, February 6th. Goldman Sachs Group raised shares of GW Pharmaceuticals PLC- from a “neutral” rating to a “buy” rating and set a $174.00 price objective on the stock in a report on Thursday, December 14th. Cantor Fitzgerald reissued a “buy” rating and set a $208.00 price objective on shares of GW Pharmaceuticals PLC- in a report on Monday, November 20th. Finally, BidaskClub lowered shares of GW Pharmaceuticals PLC- from a “buy” rating to a “hold” rating in a report on Tuesday, January 9th. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and six have given a buy rating to the company. The company has an average rating of “Hold” and an average target price of $146.38.

Shares of GW Pharmaceuticals PLC- (GWPH) traded up $1.28 on Monday, hitting $127.34. 268,704 shares of the stock were exchanged, compared to its average volume of 426,503. The stock has a market capitalization of $3,230.00, a price-to-earnings ratio of -14.40 and a beta of 2.50. The company has a quick ratio of 11.34, a current ratio of 11.44 and a debt-to-equity ratio of 0.01. GW Pharmaceuticals PLC- has a 12-month low of $92.65 and a 12-month high of $143.37.

GW Pharmaceuticals PLC- (NASDAQ:GWPH) last announced its quarterly earnings data on Monday, February 5th. The biopharmaceutical company reported ($2.43) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.03) by ($0.40). The company had revenue of $7.73 million for the quarter, compared to analysts’ expectations of $2.18 million. GW Pharmaceuticals PLC- had a negative net margin of 1,357.98% and a negative return on equity of 46.94%. equities research analysts forecast that GW Pharmaceuticals PLC- will post -9.18 EPS for the current fiscal year.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. IHT Wealth Management LLC lifted its position in GW Pharmaceuticals PLC- by 18.0% during the second quarter. IHT Wealth Management LLC now owns 656 shares of the biopharmaceutical company’s stock valued at $108,000 after purchasing an additional 100 shares during the period. Advisory Services Network LLC lifted its position in GW Pharmaceuticals PLC- by 1,109.2% during the third quarter. Advisory Services Network LLC now owns 786 shares of the biopharmaceutical company’s stock valued at $104,000 after purchasing an additional 721 shares during the period. Advisor Group Inc. lifted its position in GW Pharmaceuticals PLC- by 58.2% during the third quarter. Advisor Group Inc. now owns 949 shares of the biopharmaceutical company’s stock valued at $108,000 after purchasing an additional 349 shares during the period. Howard Hughes Medical Institute acquired a new position in GW Pharmaceuticals PLC- during the third quarter valued at $166,000. Finally, Envestnet Asset Management Inc. lifted its position in GW Pharmaceuticals PLC- by 23.7% during the fourth quarter. Envestnet Asset Management Inc. now owns 1,376 shares of the biopharmaceutical company’s stock valued at $154,000 after purchasing an additional 264 shares during the period. Institutional investors own 74.75% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This piece was first reported by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another domain, it was stolen and reposted in violation of United States and international copyright and trademark law. The original version of this piece can be viewed at https://www.americanbankingnews.com/2018/02/12/gw-pharmaceuticals-plc-gwph-stock-rating-lowered-by-zacks-investment-research.html.

GW Pharmaceuticals PLC- Company Profile

GW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company’s lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD).

Get a free copy of the Zacks research report on GW Pharmaceuticals PLC- (GWPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for GW Pharmaceuticals PLC- (NASDAQ:GWPH)

Receive News & Ratings for GW Pharmaceuticals PLC- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC- and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply